European Journal of Clinical Pharmacology

, Volume 23, Issue 2, pp 173–176 | Cite as

Pharmacokinetics of parenteral and oral melperone in man

  • L. Borgström
  • H. Larsson
  • L. Molander
Originals

Summary

The pharmacokinetics of melperone (Buronil®, Ferrosan, Sweden) was studied after administration of various parenteral and oral doses to man. After parenteral administration, the data could be fitted to a two-compartment model, but after oral dosing the distribution phase could not be separated from the elimination phase, and so an one-compartment model gave the best fit. The half-lives were about 3–4 h, except after intramuscular injection, when the half-life was about 6 h. The bioavailability of oral doses was about 60% of the intravenous injection. After the highest oral dose of 100 mg, the pharmacokinetics, expressed as AUC or Cmax, showed non-linearity, possibly due to saturation of the hepatic elimination system.

Key words

melperone neuroleptic drug dose dependent kinetics i.m. injection i.v. injection pharmacokinetics oral application 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Christensen JA, Hernestam S, Buus-Lassen J, Sterner H (1965) Pharmacological and toxicological studies on γ-(4-methylpiperidino)-p-fluorobutyrophenone (FG5111) — a new neuroleptic agent. Acta Pharmacol Toxicol 23:109–132Google Scholar
  2. 2.
    Nörgård A, Tingsgaard P, Nielsen TL (1967) Buronil ved senil konfusion og uro. (Buronil in senile confusion and anxiety). Nord Psykiatr Tidsskr 21:240–244Google Scholar
  3. 3.
    Härnryd C, Bjerkenstedt L, Lindholm H, Ljungberg L (1974) En kontrollerad klinisk prövning av Buronil och haloperidol vid förvirringstillstånd hos äldre patienter. (A controlled clinical study of Buronil and haloperidol in senile confusion) Nord Psykiatr Tidsskr 28:469–472Google Scholar
  4. 4.
    Haugen T (1967) Buronil®, et nytt butyrophenonderivat ved akutte psykiatriska lidelser. (Buronil, a new butyrophenone derivative in acute psychiatric illnesses) Ugeskr Laeg 129:1194–1197Google Scholar
  5. 5.
    Bjerkenstedt L, Härnryd C, Grimm V, Gullberg B, Sedvall G (1978) A double blind comparison of melperone and thiothixene in psychotic women using a new rating scale, the CPRS. Arch Psychiatr Nervenkr 226:157–172Google Scholar
  6. 6.
    Carlsson C, Gullberg B, Höstery U, Christensson E (1979) A double-blind study of melperone and placebo in hospitalized chronic alcoholics in postintoxication phase. Int J Clin Pharmacol Biopharm 17:341–345Google Scholar
  7. 7.
    Lindström B, Rayner S, Gullberg B, Movert R (1979) A clinical study of the effects of melperone and placebo on behavioural abnormalities in mentally retarded patients. 5th Int Congr Int Assoc Sci Study of Mental Deficiency, Jerusalem, August 1–7, 1979Google Scholar
  8. 8.
    Pöldinger WJ (1980) Ambulante Erfahrungen mit Melperon bei psychovegetativen Beschwerden unter kontrollierten Bedingungen. Therapiewoche 30:4862–4871Google Scholar
  9. 9.
    Kirkegaard A, Kirkegaard G, Geismar L, Christensen I (1981) Additional studies on side effects of melperone in long-term therapy for 1 to 15 years in psychiatric patients. Arzneim Forsch 31:737–740Google Scholar
  10. 10.
    Rowland M, Tucker G (1980) Symbols in Pharmacokinetics. J Pharmacokinet Biopharm 8:497–507Google Scholar
  11. 11.
    Loo JCK, Riegelman S (1970) Assessment pharmacokinetic constants from postinfusion blood curves obtained after intravenous infusion. J Pharm Sci 59:53–55Google Scholar
  12. 12.
    Bjerkenstedt L, Eneroth P, Härnryd C, Sedvall G (1977) Effects of melperone and thiothixene on prolactin levels in cerebrospinal fluid and plasma of psychotic woman. Arch Psychiatr Nervenkr 224:281–293Google Scholar

Copyright information

© Springer-Verlag 1982

Authors and Affiliations

  • L. Borgström
    • 1
  • H. Larsson
    • 1
  • L. Molander
    • 2
  1. 1.Department of BiochemistryResearch and Development Division, AB FerrosanMalmöSweden
  2. 2.Human Pharmacology LaboratoryResearch and Development Division, AB FerrosanMalmöSweden

Personalised recommendations